[go: up one dir, main page]

NO20090609L - Stabilt preparat omfattende en kombinasjon av et fuktighetsfolsomt legemiddel og et andre legemiddel, samt fremgangsmate for dets fremstilling - Google Patents

Stabilt preparat omfattende en kombinasjon av et fuktighetsfolsomt legemiddel og et andre legemiddel, samt fremgangsmate for dets fremstilling

Info

Publication number
NO20090609L
NO20090609L NO20090609A NO20090609A NO20090609L NO 20090609 L NO20090609 L NO 20090609L NO 20090609 A NO20090609 A NO 20090609A NO 20090609 A NO20090609 A NO 20090609A NO 20090609 L NO20090609 L NO 20090609L
Authority
NO
Norway
Prior art keywords
preparation
drug
moisture sensitive
combination
pharmaceutical
Prior art date
Application number
NO20090609A
Other languages
English (en)
Inventor
Michael Fox
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20090609L publication Critical patent/NO20090609L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Stabilt farmasøytisk preparat omfattende en kombinasjon av aktive farmasøytiske bestanddeler. Preparatet omfatter et fuktighetsfølsomt legemiddel, spesielt en inhibitor av et angiotensinomdannende enzym (ACE) som for eksempel Cilazapril, som en aktiv bestanddel, en andre farmasøytisk aktiv bestanddel som for eksempel Hydroklortiazid, og minst én farmasøytisk eksipient, hvor den fuktighetsfølsomme aktive farmasøytiske bestanddel er våtgranulert med en oppløsning av minst én farmasøytisk eksipient. Fremgangsmåter for fremstilling av slike stabile farmasøytiske preparater.
NO20090609A 2006-07-10 2009-02-09 Stabilt preparat omfattende en kombinasjon av et fuktighetsfolsomt legemiddel og et andre legemiddel, samt fremgangsmate for dets fremstilling NO20090609L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/026899 WO2008008057A1 (en) 2006-07-10 2006-07-10 Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof

Publications (1)

Publication Number Publication Date
NO20090609L true NO20090609L (no) 2009-03-13

Family

ID=37907393

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090609A NO20090609L (no) 2006-07-10 2009-02-09 Stabilt preparat omfattende en kombinasjon av et fuktighetsfolsomt legemiddel og et andre legemiddel, samt fremgangsmate for dets fremstilling

Country Status (8)

Country Link
JP (1) JP2009542806A (no)
CN (1) CN101478983A (no)
BR (1) BRPI0621867A2 (no)
CA (1) CA2659814A1 (no)
IL (1) IL196273A0 (no)
MX (1) MX2009000358A (no)
NO (1) NO20090609L (no)
WO (1) WO2008008057A1 (no)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA896851B (en) * 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors
US5006344A (en) * 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
DK9200258U4 (da) * 1992-03-11 1993-07-23 Merck & Co Inc Farmaceutisk præparat indeholdende enalapril til brug mod hypertension
WO2003075842A2 (en) * 2002-03-08 2003-09-18 Teva Pharmeceuticals Usa, Inc. Stable formulations of angiotensin converting enzyme (ace) inhibitors

Also Published As

Publication number Publication date
CN101478983A (zh) 2009-07-08
IL196273A0 (en) 2011-08-01
JP2009542806A (ja) 2009-12-03
WO2008008057A1 (en) 2008-01-17
BRPI0621867A2 (pt) 2011-12-20
MX2009000358A (es) 2009-01-27
CA2659814A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
NO20071711L (no) Sammensetninger inneholdende piperacillin, tazobactam og en aminokarboksylsyre i et natriumlaktat fortynningsmiddel
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
NO20090628L (no) Pyridizinon derivativater
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
EP2279244A4 (en) METHOD AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
BRPI0414581C1 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
BRPI0507652A (pt) composições farmacêuticas compreendendo um derivado de benzoidiazepina e um inibidor da proeìna de fusão de rsv
NO20084924L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
NO20064584L (no) Tetrahydropyridoindolderivater
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20075111L (no) Farmasoytisk sammensetning
BRPI0507654A (pt) composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv
IL188438A (en) A heterocyclic active drug with five benzoposes, or a pharmaceutically acceptable salt and aster salts product, as well as compounds containing them and their use as @catol - o @ - @ of @ enzyme @ dead G iltransferase @@ comtI
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
WO2007101710A8 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2007128086A3 (en) Novel viral replication inhibitor
CL2009001183A1 (es) Formulación farmacéutica sólida que comprende a) cilostazol, b) 10 a 90% de un almidón pregelatinizado c) uno o más tipos de ingredientes entéricos, y d) un ácido orgánico.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application